Glucose is a key driver for GLUT1-mediated nanoparticles internalization in breast cancer cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Venturelli, Leonardo ^a,b,c   Nappini, Silvia ^b   Bulfoni, Michela ^c   Gianfranceschi, Giuseppe ^c   Dal Zilio, Simone ^b   Coceano, Giovanna ^a,b   Del Ben, Fabio ^a,c   Turetta, Matteo ^c   Scoles, Giacinto ^c   Vaccari, Lisa ^d   Cesselli, Daniela ^c   Cojoc, Dan ^b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b CNR Institute of Materials   (Italy)

^c UNIVERSITY OF UDINE   (Italy)

^d SINCROTRONE TRIESTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; GLUCOSE TRANSPORTER 1; MAGNETITE NANOPARTICLE; SLC2A1 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; CHEMISTRY; DRUG EFFECTS; EPITHELIUM CELL; FEMALE; GENETICS; HUMAN; MCF-7 CELL LINE; MESODERM; METABOLISM; PATHOLOGY; THERMOTHERAPY;

BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; GLUCOSE; GLUCOSE TRANSPORTER TYPE 1; HUMANS; HYPERTHERMIA, INDUCED; MAGNETITE NANOPARTICLES; MCF-7 CELLS; MESODERM;

EID: 84958979441     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep21629     Document Type: Article

References (52)

1. Warburg, O., Wind, F. & Negelein, E. The metabolism of tumors in the body. J. Gen. Physiol. 8, 519-530 (1927).
2. Ngo, H., Tortorella, S. M., Ververis, K. & Karagiannis, T. C. The Warburg effect: molecular aspects and therapeutic possibilities. Mol. Biol. Rep. 1-10 (2014). doi: 10.1007/s11033-014-3764-7.
3. Vander Heiden, M. G., Cantley, L. C. & Thompson, C. B. Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation. Science 324, 1029-1033 (2009).
4. Ward, P. S. & Thompson, C. B. Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate. Cancer Cell 21, 297-308 (2012).
5. Samudio, I., Fiegl, M. & Andreeff, M. Mitochondrial Uncoupling and the Warburg Effect: Molecular Basis for the Reprogramming of Cancer Cell Metabolism. Cancer Res. 69, 2163-2166 (2009).
6. Gallamini, A., Zwarthoed, C. & Borra, A. Positron Emission Tomography (PET) in Oncology. Cancers 6, 1821-1889 (2014).
7. Vicente, A. M. G. et al. Glycolytic activity with 18F-FDG PET/CT predicts final neoadjuvant chemotherapy response in breast cancer. Tumor Biol. 1-8 (2014). doi: 10.1007/s13277-014-2495-7.
8. Alvarez, J. V. et al. Oncogene pathway activation in mammary tumors dictates [18F]-FDG-PET uptake. Cancer Res. canres.1235. 2014 (2014). doi: 10.1158/0008-5472.CAN-14-1235.
9. Pathiraja, T. N. et al. TRIM24 links glucose metabolism with transformation of human mammary epithelial cells. Oncogene (2014). doi: 10.1038/onc.2014.220.
10. Mueckler, M. & Thorens, B. The SLC2 (GLUT) family of membrane transporters. Mol. Aspects Med. 34, 121-138 (2013).
11. Chen, C.-L., Chu, J.-S., Su, W.-C., Huang, S.-C. & Lee, W.-Y. Hypoxia and metabolic phenotypes during breast carcinogenesis: expression of HIF-1α, GLUT1, and CAIX. Virchows Arch. 457, 53-61 (2010).
12. Cao, J. et al. Targeted Cancer Therapy with a 2-Deoxyglucose-Based Adriamycin Complex. Cancer Res. 73, 1362-1373 (2013).
13. Shan, X. H. et al. Targeting Glut1-overexpressing MDA-MB-231 cells with 2-deoxy-d-glucose modified SPIOs. Eur. J. Radiol. 81, 95-99 (2012).
14. Chan, D. A. et al. Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality. Sci. Transl. Med. 3, 94ra70-94ra70 (2011).
15. Xu, R. et al. Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia. Cancer Res. 65, 613-621 (2005).
16. Liu, P. et al. Highly water-soluble platinum(II) complexes as GLUT substrates for targeted therapy: improved anticancer efficacy and transporter-mediated cytotoxic properties. Chem. Commun. 49, 2421-2423 (2013).
17. Butler, E. B., Zhao, Y., Munoz-Pinedo, C., Lu, J. & Tan, M. Stalling the Engine of Resistance: Targeting Cancer Metabolism to Overcome Therapeutic Resistance. Cancer Res. 73, 2709-2717 (2013).
18. Chavez, K. J., Garimella, S. V. & Lipkowitz, S. Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer. Breast Dis. 32, 35 (2010).
19. Yin, K.B. The Mesenchymal-Like Phenotype of the MDA-MB-231 Cell Line in Breast Cancer - Focusing Tumor Microenvironment, Stem cells and Metastasis (eds Gunduz, M. & Gunduz, E) Ch. 18, 385-402 (InTech, 2011).
20. Balliet, R. M. et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle Georget. Tex 10, 4065-4073 (2011).
21. Hirschhaeuser, F., Sattler, U. G. A. & Mueller-Klieser, W. Lactate: A Metabolic Key Player in Cancer. Cancer Res. 71, 6921-6925 (2011).
22. Estrella, V. et al. Acidity Generated by the Tumor Microenvironment Drives Local Invasion. Cancer Res. 73, 1524-1535 (2013).
23. Cheraghipour, E. Citrate capped superparamagnetic iron oxide nanoparticles used for hyperthermia therapy. J. Biomed. Sci. Eng. 05, 715-719 (2012).
24. Nigam, S., Barick, K. C. & Bahadur, D. Development of citrate-stabilized Fe3O4 nanoparticles: Conjugation and release of doxorubicin for therapeutic applications. J. Magn. Magn. Mater. 323, 237-243 (2011).
25. Lukianova-Hleb, E. Y. et al. Improved Cellular Specificity of Plasmonic Nanobubbles versus Nanoparticles in Heterogeneous Cell Systems. PLoS ONE 7, e34537 (2012).
26. Yamamoto, M., Patel, N. A., Taggart, J., Sridhar, R. & Cooper, D. R. A shift from normal to high glucose levels stimulates cell proliferation in drug sensitive MCF-7 human breast cancer cells but not in multidrug resistant MCF-7/ADR cells which overproduce PKC-betaII. Int. J. Cancer J. Int. Cancer 83, 98-106 (1999).
27. Chapman, S. et al. Nanoparticles for cancer imaging: The good, the bad, and the promise. Nano Today 8, 454-460 (2013).
28. Nayak, L. et al. Rare cell capture technology for the diagnosis of leptomeningeal metastasis in solid tumors. Neurology 80, 1598-1605 (2013).
29. Frithiof, H., Welinder, C., Larsson, A.-M., Rydén, L. & Aaltonen, K. A novel method for downstream characterization of breast cancer circulating tumor cells following Cell Search isolation. J. Transl. Med. 13, 126, 10.1186/s12967-015-0493-1 (2015).
30. Friedlander, T. W., Premasekharan, G. & Paris, P. L. Looking back, to the future of circulating tumor cells. Pharmacol. Ther. 142, 271-280 (2014).
31. Schlereth, B. et al. Eradication of Tumors from a Human Colon Cancer Cell Line and from Ovarian Cancer Metastases in Immunodeficient Mice by a Single-Chain Ep-CAM-/CD3-Bispecific Antibody Construct. Cancer Res. 65, 2882-2889 (2005).
32. Mego, M., Mani, S. A. & Cristofanilli, M. Molecular mechanisms of metastasis in breast cancer-clinical applications. Nat Rev Clin Oncol 7, 693-701 (2010).
33. Ozkumur, E. et al. Inertial Focusing for Tumor Antigen-Dependent and -Independent Sorting of Rare Circulating Tumor Cells. Sci. Transl. Med. 5, 179ra47-179ra47 (2013).
34. Aktas, B. et al. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res. BCR 11, R46 (2009).
35. Fan, T., Zhao, Q., Chen, J. J., Chen, W.-T. & Pearl, M. L. Clinical significance of circulating tumor cells detected by an invasion assay in peripheral blood of patients with ovarian cancer. Gynecol. Oncol. 112, 185-191 (2009).
36. Baccelli, I. et al. Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. Nat. Biotechnol. 31, 539-544 (2013).
37. Yokobori, T. et al. Plastin3 Is a Novel Marker for Circulating Tumor Cells Undergoing the Epithelial-Mesenchymal Transition and Is Associated with Colorectal Cancer Prognosis. Cancer Res. 73, 2059-2069 (2013).
38. Satelli, A. et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 74, 1645-1650 (2014).
39. 4 metal cores. Nanotechnology 25, 025101 (2014).
40. Macheda, M. L., Rogers, S. & Best, J. D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202, 654-662 (2005).
41. Laudański, P., Swiatecka, J., Kovalchuk, O. & Wołczyński, S. Expression of GLUT1 gene in breast cancer cell lines MCF-7 and MDA-MB-231. Ginekol. Pol. 74, 782-785 (2003).
42. Kobayashi, T. Cancer hyperthermia using magnetic nanoparticles. Biotechnol. J. 6, 1342-1347 (2011).
43. Ceresa, C., Bravin, A., Cavaletti, G., Pellei, M. & Santini, C. The combined therapeutical effect of metal-based drugs and radiation therapy: the present status of research. Curr. Med. Chem. 21, 2237-2265 (2014).
44. Singh, A. & Settleman, J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29, 4741-4751 (2010).
45. Massart R, inventor; Agence Nationale de Valorisation de la Recherche (ANVAR), assignee. Magnetic fluids and process for obtaining them. United States patent US 4, 329, 241. 1982 May 11.
46. Nappini, S. et al. Surface Charge and Coating of CoFe2O4 Nanoparticles: Evidence of Preserved Magnetic and Electronic Properties. J. Phys. Chem. C 119, 25529-25541 (2015).
47. Rasband, W.S. & Eliceiri, K.W. NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9, 671-675 (2012).
48. Kawata, H. et al. RhoC Upregulation Is Correlated with Reduced E-cadherin in Human Breast Cancer Specimens After Chemotherapy and in Human Breast Cancer MCF-7 Cells. Horm. Cancer (2014). doi: 10.1007/s12672-014-0199-5.
49. Hassanein, M. et al. Development of High-Throughput Quantitative Assays for Glucose Uptake in Cancer Cell Lines. Mol. Imaging Biol. 13, 840-852 (2010).
50. Meguro, R. et al. Nonheme-iron histochemistry for light and electron microscopy: a historical, theoretical and technical review. Arch. Histol. Cytol. 70, 1-19 (2007).
51. Borgohain, C., Senapati, K. K., Mishra, D., Sarma, K. C. & Phukan, P. A new CoFe2O4-Cr2O3-SiO2 fluorescent magnetic nanocomposite. Nanoscale 2, 2250 (2010).
52. Jacques, S. L. Optical properties of biological tissues: a review. Phys. Med. Biol. 58, R37-R61 (2013).